What's Happening?
Arrowhead Pharmaceuticals has received marketing authorization from the European Commission for its drug REDEMPLO (plozasiran), designed to reduce triglyceride levels in adults with familial chylomicronemia syndrome (FCS). This approval marks REDEMPLO as the first
and only small interfering RNA (siRNA) treatment authorized in the EU for FCS, which can be diagnosed either clinically or genetically. The drug works by targeting and suppressing the production of apolipoprotein C-III, a liver-produced protein that raises triglyceride levels. Clinical trials have shown that REDEMPLO can significantly reduce triglyceride levels and the incidence of acute pancreatitis, a common complication of FCS.
Why It's Important?
The approval of REDEMPLO in the EU is significant as it provides a new treatment option for patients with FCS, a rare and severe condition characterized by extremely high triglyceride levels and a heightened risk of acute pancreatitis. This development addresses a critical unmet need, offering a treatment that does not require genetic confirmation, thus broadening access to more patients. The drug's ability to significantly lower triglyceride levels could improve the quality of life for those affected by FCS, reducing the risk of life-threatening complications and chronic pain associated with the condition.
What's Next?
Following the EU approval, Arrowhead Pharmaceuticals plans to engage with national health authorities and healthcare communities across the EU to facilitate the availability of REDEMPLO. The company is also continuing its global regulatory efforts, having already secured approvals in the U.S., Canada, China, and Australia. Further clinical trials are underway to explore the drug's efficacy in other related conditions, potentially expanding its therapeutic applications.
